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Nature contains a treasure trove of small molecule ingredients that can improve health, wellness and nutrition. 
However, most of these ingredients have “issues”: the organism that makes the compound of interest is too 
rare, too hard to grow or does not make enough of it. Hence, the ingredient is not available at the right quality, 
the right price nor the necessary amount. These issues need to be solved in order to allow a larger society 
having access to these valuable ingredients in a sustainable manner at low costs. Evolva is leader in metabolic 
engineering of yeast for the production by fermentation of a diverse array of small molecule ingredients. The 
small molecule ingredients introduced to the market by Evolva include Resveratrol, Nootkatone, Valencene and 
Vanillin. Evolva and its commercial partner will launch the next-generation stevia sweetener EverSweetTM in 
2018. All of these molecules are produced in a sustainable, reliable, cost-effective production at consistent 
quality by fermentation of engineered yeast strains, using abundant, inexpensive raw materials. Of particular 
interest to Evolva are the terpenes, which are known to work in a wide range of high value applications including 
sweeteners, flavors and fragrances, personal care, as well as human and animal health products. In spite of 
proven efficacy, there has been relatively little commercial development of terpene-based ingredients, mostly 
due to their high production cost. Here, we will present a number of terpene-based Evolva ingredient projects 
such as e.g. the stevia pathway, which use Evolva’s technology platforms, allowing us to produce these 
ingredients in an efficient and sustainable way. 
 
Biosynthesis of steviol glycosides via the mevalonate 
pathway. The geranyl-geranyl-diphosphate-synthase 
(GGDPS) catalyzes the formation of the diterpene 
precursor geranylgeranyl-PP, which is converted in 
subsequent steps to steviol. Steviol is then 
glycosylated by the action of glycosyl-transferases, 
giving rise to the premium steviol-glucoside 
sweeteners RebD and RebM, respectively. 
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